KLOW is a vendor‑blended peptide mix of KPV, LL‑37, oxytocin and Wolverine that users take mainly for tissue and injury repair, general recovery and, to a much lesser extent, gut healing. The community’s modal regimen is a daily dose around 4 mg, with reported amounts ranging from 15 µg up to 40 mg; timing and cycling are left to the individual. The only clear limitation is that it has no FDA‑approved indication, so all human use is off‑label or compounded. Reported side effects are modest: occasional changes in sleep or dreams, occasional nausea or GI upset, and rare injection‑site irritation or fluid retention.
Data last updated
Measured on 4 of 6 axes
Evidence shape
The only published data for KLOW come from animal‑only, preclinical mechanistic research, so human evidence is absent. Across the literature there is a single mapped indication and no registered or completed human trials, meaning the peptide has no demonstrated efficacy or safety in people. This lack of any human‑level data, combined with no ongoing or finished studies, signals that the peptide remains entirely experimental.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 23 out-of-stock offers not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How KLOW is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Among those who specified a regimen, the most common pattern was daily dosing of around 4 mg, with a broad range from 15 µg to 40 mg; smaller groups used it twice‑daily, three times weekly, twice weekly, or weekly, and no cycling was reported.